You have just been told you have advanced lung cancer. Within days, your oncologist may mention terms you have never heard before — EGFR, PD-L1, ALK, checkpoint inhibitors, driver mutations. Then comes the question you likely did not expect so soon: which treatment should you have?

Chemotherapy? Immunotherapy? A targeted drug? Some combination of all three? This decision is one of the most consequential in your cancer care — and the right answer depends less on the diagnosis itself and more on the molecular fingerprint inside your specific tumor.

This article explains how each of the three major treatment strategies for advanced lung cancer works, what oncologists look for when choosing between them, and why expert specialist input on your tumor's profile can affect your treatment path.

Advanced Lung Cancer: A Disease That Looks Different Under the Microscope

Lung cancer is not a single disease. According to the National Cancer Institute, non-small cell lung cancer (NSCLC) accounts for most cases and includes several subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Small cell lung cancer (SCLC) is less common but typically grows and spreads more quickly.

When cancer is described as advanced, it usually means it has spread beyond the lung tissue — to nearby lymph nodes, the other lung, or distant organs such as the brain, liver, or bone. At this stage, treatment for most patients focuses on slowing the cancer's growth, managing symptoms, and preserving quality of life.

What makes advanced lung cancer particularly complex is that two patients with the same stage and subtype can have tumors that behave entirely differently at the molecular level. That difference drives treatment selection today — which is why understanding your tumor's profile is important before any treatment begins.

Your Tumor's Molecular Profile: The Foundation of Treatment Choice

Before making a confident treatment recommendation, your oncologist needs to understand what is driving your cancer's growth at the molecular level. This is done through biomarker testing — also called molecular profiling, genomic testing, or tumor profiling.

Biomarker testing analyzes a sample of your tumor (from a biopsy) or, in some cases, a blood sample (liquid biopsy), to identify specific genetic mutations, gene rearrangements, and protein expressions. For advanced NSCLC, markers most commonly tested include EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, HER2, and KRAS mutations, as well as PD-L1 expression. Peer-reviewed research on predictive biomarkers in NSCLC identifies multiple actionable molecular markers in advanced lung cancer — each with direct implications for treatment choice.

Chemotherapy, targeted therapy, and immunotherapy each work through entirely different mechanisms — and each tends to be most effective in a specific molecular context. Starting a treatment that does not match your tumor's profile may mean a slower response, more side effects, and a delay in receiving the approach most likely to work for your specific cancer.

Chemotherapy: Broad-Acting and Still a Relevant Choice

Chemotherapy uses drugs that travel through the bloodstream and attack cells that divide rapidly — including cancer cells. For many years, it was the primary systemic treatment for advanced lung cancer. It remains an important option today, particularly for patients whose tumors do not carry actionable driver mutations and who may not be strong candidates for immunotherapy alone.

For advanced NSCLC, platinum-based chemotherapy combinations — pairing carboplatin or cisplatin with a second agent — are commonly used. In some settings, chemotherapy is combined with immunotherapy to try to improve response.

Because chemotherapy acts on all rapidly dividing cells, not just cancer cells, it tends to cause side effects such as fatigue, nausea, hair thinning, and an increased risk of infection. If you are already on or considering chemotherapy, it may help to read about managing fatigue and shortness of breath during lung cancer chemotherapy, which outlines what patients commonly experience and practical ways to prepare.

Chemotherapy may be the most appropriate choice when no targetable driver mutation is identified and PD-L1 expression is low. The key point is that this conclusion should follow a complete biomarker workup — not be assumed as the default before testing is complete.

Targeted Therapy: Precision Treatment for Specific Mutations

Targeted therapy is designed to block specific molecular signals that cancer cells rely on to grow and survive. Unlike chemotherapy, it does not act broadly on all dividing cells — it acts on a defined molecular target. For the right patient, this precision may translate into a stronger response and a different side effect profile.

In advanced NSCLC, the most commonly targeted drivers include:

• EGFR mutations — among the most frequent driver mutations in NSCLC, particularly in patients who have never smoked or who have adenocarcinoma. A class of drugs known as EGFR tyrosine kinase inhibitors (TKIs) may be used when this mutation is present.
• ALK rearrangements — found in a smaller subset of NSCLC patients. ALK inhibitors have shown strong activity in this population.
• ROS1, RET, MET, NTRK, BRAF, HER2, and KRAS alterations — each has approved or investigational targeted agents associated with it.

According to consensus recommendations from lung cancer researchers, identifying EGFR mutations and other driver alterations should happen before treatment starts. Giving immunotherapy to a patient with an EGFR mutation, for example, may not provide the expected benefit — and could delay access to a more appropriate targeted treatment.

Targeted therapy is typically taken as a daily oral pill rather than an infusion, which many patients find more convenient. However, resistance can develop over time. When this happens, additional molecular testing is usually needed to understand why the tumor stopped responding and what treatment should come next.

Immunotherapy: Working With Your Immune System to Fight Cancer

Immunotherapy works differently from both chemotherapy and targeted therapy. Rather than directly attacking cancer cells, it removes molecular restraints from your immune system — allowing your own immune cells to recognize and attack cancer more effectively.

The most widely used immunotherapy drugs in advanced lung cancer are checkpoint inhibitors, which block proteins called PD-1 or PD-L1. As the American Cancer Society explains, these proteins normally help prevent the immune system from attacking healthy tissue — but cancer cells can exploit them to evade immune surveillance. Checkpoint inhibitors block this evasion mechanism.

Immunotherapy may be given alone or in combination with chemotherapy. The level of PD-L1 expression in your tumor is one of the key factors used to estimate how likely immunotherapy is to be effective. Patients with high PD-L1 expression may respond well to immunotherapy alone. Those with lower expression may still benefit, particularly when immunotherapy is combined with chemotherapy.

The side effects of immunotherapy differ from those of chemotherapy. They include immune-related reactions — called immune-related adverse events — that can affect the lungs, liver, skin, intestines, or endocrine glands. These require careful monitoring and, when significant, may need treatment with corticosteroids.

Critically, patients with EGFR or ALK driver mutations may not respond as well to immunotherapy. This is one of the strongest reasons why comprehensive biomarker testing must come before any treatment decision for advanced NSCLC.

When These Approaches Are Used Together

In practice, these three treatment categories are not always used in isolation. Combination and sequential approaches are increasingly common for advanced lung cancer. Examples include:

• Chemotherapy combined with immunotherapy as an initial approach when driver mutations are absent
• One targeted therapy followed by a second or third-generation agent when resistance develops
• Immunotherapy used as maintenance after an initial combination phase

Treatment options for advanced lung cancer keep changing. New agents, combinations, and clinical trial options emerge regularly. This is another reason why staying connected to specialist expertise — through your primary oncologist or an additional consultation — matters throughout your care and beyond initial diagnosis.

Common Questions Patients Ask About Treatment Selection

When patients first learn that treatment choice depends on their tumor's molecular profile, several questions commonly come up:

• Was my tumor fully tested before this recommendation was made?
• If I have an EGFR mutation, does that mean chemotherapy is never appropriate for me?
• What happens if my biomarker test comes back with no actionable mutations?
• Can I still be eligible for a clinical trial if I have already received one line of treatment?
• How do I know if the oncologist interpreting my molecular profile has deep expertise in lung cancer specifically?

These are important, valid questions — and in many cases, a specialist second opinion is the most reliable way to get clear answers grounded in current evidence.

Why Many Patients Seek a Second Opinion Before Committing to Treatment

Choosing between immunotherapy, targeted therapy, chemotherapy, or a combination requires both biomarker test results and the expertise to interpret them in the context of your full clinical picture. This is where a specialist second opinion can help.

Patients often seek additional expert input when their tumor profiling covered only a limited number of markers and they are unsure whether testing was comprehensive enough. Others seek a second opinion to confirm that a recommendation aligns with current evidence, when they have received conflicting advice, when cancer stopped responding to first-line treatment, or when they want to explore clinical trial options based on their molecular results.

Many patients also find it difficult to fully absorb complex treatment discussions due to cognitive fog. Understanding how chemo brain can affect patients during lung cancer treatment explains why having a caregiver and requesting written expert summaries is important when making major treatment decisions.

How an Online Oncology Consultation Works

An online consultation with a specialist thoracic oncologist allows you to have your case reviewed by an expert regardless of where you live. The process does not require travel to a major cancer center or a lengthy wait for an in-person appointment.

At HealthUnwired, a typical consultation involves uploading your pathology report, biomarker or molecular profiling results, and imaging (CT scan, PET scan, or MRI). A board-certified lung cancer specialist reviews your case and provides a written or video consultation that addresses your specific questions, clarifies your treatment options, and produces a document you can share with your local oncology team.

Benefits of Consulting a Specialist Online

• Speed: Expert input without waiting months for an in-person specialist appointment
• Access: Reach thoracic oncology expertise regardless of your country or healthcare system
• Confidence: Knowing your plan has been independently reviewed reduces uncertainty and supports clearer decision-making
• Clarity: Understanding why a specific treatment was recommended — and what your biomarker results mean — helps you ask better questions at every future appointment
• Coordination: Written specialist summaries can be shared directly with your treating team to inform ongoing care

Preparing for Your Consultation

Getting the right documents before your consultation helps the specialist give you better advice. Try to bring:

• Your biopsy or pathology report
• Molecular profiling or biomarker test results — including EGFR, ALK, PD-L1, and any additional markers tested
• Imaging reports and scan files (CT, PET, MRI)
• Your oncologist's current treatment recommendation or plan
• A written list of your most important questions

If your biomarker testing was limited or reports are incomplete, the specialist may recommend additional testing before a full treatment review is possible. That guidance itself is helpful.

Next Steps After Your Consultation

Following a specialist review, you will typically receive a written summary of findings and recommendations. You can use this to have a more informed conversation with your local oncologist, explore clinical trial eligibility, or pursue additional molecular testing if gaps were identified in your workup.

The goal is not to replace your treating team — it is to give both you and them the benefit of an additional expert perspective at one of the most consequential decision points in your cancer care.

Ready to Have Your Treatment Plan Reviewed by a Specialist?

If you or someone in your family has been diagnosed with advanced lung cancer and is weighing immunotherapy, targeted therapy, or chemotherapy — or is unsure whether biomarker testing so far has been comprehensive enough — a specialist consultation can help answer that question.

Upload your pathology and molecular profiling results, browse specialist profiles, and book a paid online consultation with a thoracic oncology expert at HealthUnwired. Everyone facing advanced lung cancer should have access to expert input, wherever they are in the world.

When to talk to your doctor: If you have been diagnosed with advanced lung cancer and have not yet had comprehensive biomarker testing, ask your oncologist specifically about molecular profiling before treatment begins. If treatment has already started and you have questions about whether the approach matches your tumor's profile, raise those concerns directly — or seek a specialist second opinion. Early clarity on biomarker-driven treatment selection can help your care.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.